More milestones for AC Immune in Lilly Morphomer Tau partnership

23 March 2020

As shares are falling around the world due to the coronavirus pandemic, those of Swiss clinical-stage biotech firm AC Immune (Nasdaq: ACIU) were up 14.14% at $5.41 by mid-morning, after the company updated on its collaboration with Eli Lilly (NYSE: LLY).

AC Immune said it will receive a second milestone payment of 10 million Swiss francs ($10.1 million) from Lilly on or before March 31, 2020, related to development progress in the small molecule Morphomer Tau aggregation inhibitor program.

The multi-year collaboration agreement between Lilly and AC Immune was originally announced in December 2018 and focuses on the broad development of Morphome Tau aggregation inhibitors for Alzheimer’s disease (AD) and other neurodegenerative diseases.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK